Actionable news
All posts from Actionable news

TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata

MALVERN, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (TLOG) today announced that it has an open U.S. Investigational New Drug application in support of a Phase 2 clinical trial of suberohydroxamic acid (4-methoxycarbonyl) phenyl ester (SHAPE) in approximately forty patients with alopecia areata.

SHAPE is a novel HDAC inhibitor being developed for topical treatment of cutaneous T-cell lymphoma, or CTCL, and is currently being evaluated in a Phase 2 clinical trial. SHAPE is designed to maximize HDAC inhibition locally in the skin with limited systemic exposure.

Alopecia areata is an autoimmune skin disease resulting in the loss of hair on the scalp and elsewhere on the body. Alopecia areata occurs in males and females of all ages, but onset often occurs in childhood. Over 6.6 million people in the United States have or will develop alopecia areata at some point in their lives. FDA has identified alopecia areata to be one of the few disease states to be developed under the Patient-Focused Drug Development Initiative based upon multiple criteria including disease severity and unmet medical needs.

"We are excited to advance SHAPE into a second indication and another Phase 2 trial," said J. Kevin Buchi, President and Chief Executive Officer of TetraLogic. "A topical therapy which minimizes systemic exposure could provide an...